Gross total resection with fluorescence could lead to improved overall survival rates: a systematic review and meta-analysis

References

• Cavenee WK, Figarella ‑Branger D, Louis DN, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803–20.
   PubMed Web of Science ®Google Scholar
• Coburger J, Hagel V, Wirtz CR, König R. Surgery for glioblastoma: impact of the combined use of 5-aminolevulinic acid and intraoperative MRI on extent of resection and survival. PLOS One 2015;10:e0131872.
   PubMed Web of Science ®Google Scholar
• Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190–8.
   PubMed Web of Science ®Google Scholar
• Eljamel S. 5-ALA fluorescence image guided resection of glioblastoma multiforme: a meta-analysis of the literature. IJMS 2015;16:10443–56.
   Web of Science ®Google Scholar
• Eljamel MS, Mahboob SO. The effectiveness and cost-effectiveness of intraoperative imaging in high-grade glioma resection; a comparative review of intraoperative ALA, fluorescein, ultrasound and MRI. Photodiagnosis Photodyn Ther 2016;16:35–43.
   PubMed Web of Science ®Google Scholar
• Koc K, Anik I, Cabuk B, Ceylan S. Fluorescein sodium-guided surgery in glioblastoma multiforme: a prospective evaluation. Br J Neurosurg 2008;22:99–103.
   PubMed Web of Science ®Google Scholar
• Hadjipanayis CG, Stummer W. 5-ALA and FDA approval for glioma surgery. J Neurooncol 2019;141:479–86.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services Public Health Service Food and Drug Administration Center For Drug Evaluation and Research. Pharmacology/Toxicology Nda/Bla Review And Evaluation. 2016. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208630Orig1s000PharmR.pdf Available on 18/04/2020
   Google Scholar
• Neidert MC, Hostettler IC, Burkhardt JK, et al. The influence of intraoperative resection control modalities on survival following gross total resection of glioblastoma. Neurosurg Rev 2016;39:401–9.
   PubMed Web of Science ®Google Scholar
• Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme. Am J Clin Oncol 2013;36:261–8.
   PubMed Web of Science ®Google Scholar
• Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg 2012;117:1032–8.
   PubMed Web of Science ®Google Scholar
• Gorlia T, Stupp R, Brandes AA, et al. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC brain tumour group phase I and II clinical trials. Eur J Cancer 2012;48:1176–84.
   PubMed Web of Science ®Google Scholar
• Clarke JL, Ennis MM, Yung WK, North American Brain Tumor Consortium, et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol 2011;13:1118–24.
   PubMed Web of Science ®Google Scholar
• Kuroiwa T, Kajimoto Y, Ohta T. Development of a fluorescein operative microscope for use during malignant glioma surgery: a technical note and preliminary report. Surg Neurol 1998;50:41–8.
   PubMedGoogle Scholar
• Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7:392–401.
   PubMed Web of Science ®Google Scholar
• Stummer W, Nestler U, Stockhammer F, et al. Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA. J Neurooncol 2011;103:361–70.
   PubMed Web of Science ®Google Scholar
• Department of health and human services. Public health service. Food and drug administration. Centre for drug administration and research. Pharmacology/toxicology review and evaluation. 2006. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021980s000_PharmR.pdf Available on 18/04/2020
   Google Scholar
• Hansen RW, Pedersen CB, Halle B. Comparison of 5-aminolevulinic acid and sodium fluorescein for intraoperative tumor visualization in patients with high-grade gliomas: a single-center retrospective study. J Neurosurg 2019; 4:1–8.
   Google Scholar
• Yano H, Nakayama N, Ohe N, Miwa K, Shinoda J, Iwama T. Pathological analysis of the surgical margins of resected glioblastomas excised using photodynamic visualization with both 5-aminolevulinic acid and fluorescein sodium. J Neurooncol 2017;133:389–97.
   PubMed Web of Science ®Google Scholar
• Litofsky NS, Bauer AM, Kasper RS, Sullivan CM, Dabbous OH, Glioma Outcomes Project Investigators. Image-guided resection of high-grade glioma: patient selection factors and outcome. Neurosurg Focus 2006;20:E16.
   PubMedGoogle Scholar
• Hauser SB, Kockro RA, Actor B, Sarnthein J, Bernays RL. Combining 5-aminolevulinic acid fluorescence and intraoperative magnetic resonance imaging in glioblastoma surgery: a histology-based evaluation. Neurosurgery 2016;78:475–83.
   PubMed Web of Science ®Google Scholar
• Gessler F, Bernstock JD, Braczynski A, et al. Surgery for glioblastoma in light of molecular markers: impact of resection and MGMT promoter methylation in newly diagnosed IDH-1 wild-type glioblastomas. Neurosurgery 2019;84:190–7.
   PubMed Web of Science ®Google Scholar
• Dunn J, Baborie A, Alam F, et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 2009;101:124–31.
   PubMed Web of Science ®Google Scholar
• Aldave G, Tejada S, Pay E, et al. Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic Acid-guided surgery. Neurosurgery 2013; 72:915–20. discussion 920-1.
   PubMed Web of Science ®Google Scholar
• Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 2000; 93:1003–13.
   PubMed Web of Science ®Google Scholar
• Smith SJ, Diksin M, Chhaya S, Sairam S, Estevez-Cebrero MA, Rahman R. The Invasive Region of Glioblastoma Defined by 5ALA Guided Surgery Has an Altered Cancer Stem Cell Marker Profile Compared to Central Tumour. Int J Mol Sci 2017; 18:2452.
   PubMed Web of Science ®Google Scholar
• Acerbi F, Broggi M, Eoli M, et al. Is fluorescein-guided technique able to help in resection of high-grade gliomas? Neurosurg Focus 2014; 36:E5.
   PubMed Web of Science ®Google Scholar
• Acerbi F, Broggi M, Schebesch KM, et al. Fluorescein-Guided Surgery for Resection of High-Grade Gliomas: A Multicentric Prospective Phase II Study (FLUOGLIO). Clin Cancer Res 2018; 24:52–61.
   PubMed Web of Science ®Google Scholar
• Hauser SB, Kockro RA, Actor B, Sarnthein J, Bernays RL. Combining 5-Aminolevulinic Acid Fluorescence and Intraoperative Magnetic Resonance Imaging in Glioblastoma Surgery: A Histology-Based Evaluation. Neurosurgery 2016; 78:475–83.
   PubMed Web of Science ®Google Scholar
• Michael AP, Watson VL, Ryan D, Delfino KR, Bekker SV, Cozzens JW. Effects of 5-ALA dose on resection of glioblastoma. J Neurooncol 2019; 141:523–31.
   PubMed Web of Science ®Google Scholar